Pfizer
The Latest
-
Pfizer Expands RSV Vaccine Ambitions to Younger High-Risk Adults
Pfizer is setting a new course in the battle against respiratory syncytial virus (RSV) by targeting a younger demographic with its vaccine, Abrysvo. In a significant development, the pharmaceutical giant announced that its late-stage clinical trials indicate the vaccine's potential to shield adults aged 18 to 59 who are at an elevated risk of severe RSV infections. 
Pfizer is setting a new course in the battle against respiratory syncytial virus (RSV) by targeting a younger demographic with its vaccine, Abrysvo. In a significant development, the pharmaceutical giant announced that its late-stage clinical trials indicate the vaccine's potential to shield adults aged 18 to 59 who are at an elevated risk of severe RSV infections. -
Pfizer Halts Development of Promising Obesity Pill Amid Disappointing Trial Results
This development marks a major blow to Pfizer's aspirations of entering the rapidly growing obesity treatment market, which analysts project could reach $100 billion by the end of this decade. 
This development marks a major blow to Pfizer's aspirations of entering the rapidly growing obesity treatment market, which analysts project could reach $100 billion by the end of this decade. -
Study Finds Vaccinated Lactating Moms’ Breast Milk Tainted With COVID Vaccines
Mothers and would-be moms who haven't been vaccinated against COVID would be glad to know they didn't get jabbed after a new study found something very interesting-even concerning. 
Mothers and would-be moms who haven't been vaccinated against COVID would be glad to know they didn't get jabbed after a new study found something very interesting-even concerning. -
Moderna mRNA Patent Ignites Lawsuit Against Pfizer-BioNTech
Pfizer and BioNTech are being sued by Moderna for patents on life-saving technology that they claim to have filed years ago. 
Pfizer and BioNTech are being sued by Moderna for patents on life-saving technology that they claim to have filed years ago. -
Paxlovid COVID-19 Pill Effective For Elderly But May Not Benefit Young Adults
When administered soon after infection, Paxlovid reduced hospitalizations among those 65 and older by almost 75%, according to the study. When administered soon after infection, Paxlovid reduced hospitalizations among those 65 and older by almost 75%, according to the study. -
U.S. Panel Set To Authorize COVID Vaccine For Young Children
Pfizer and Moderna vaccines use messenger RNA technology to deliver genetic code for the coronavirus spike protein to human cells. 
Pfizer and Moderna vaccines use messenger RNA technology to deliver genetic code for the coronavirus spike protein to human cells. -
COVID-19 Vaccines For Young Children Could Roll Out 'In Earnest' June 21, White House Says
Pfizer and its partner BioNTech on Wednesday completed their filing with the U.S. FDA to seek authorization for their COVID-19 vaccine in young children. 
Pfizer and its partner BioNTech on Wednesday completed their filing with the U.S. FDA to seek authorization for their COVID-19 vaccine in young children. -
Pfizer To Acquire Migraine Drug Maker Biohaven For $11.6 Billion
Pfizer's offer represents a 78.6% premium to Biohaven Pharmaceutical's latest closing price. 
Pfizer's offer represents a 78.6% premium to Biohaven Pharmaceutical's latest closing price. -
Pfizer, J&J & Other Major Pharma Companies Will Continue To Supply Medicines To Russia
"Always with sanctions, medicines are excluded," Pfizer CEO Albert Bourla said. 
"Always with sanctions, medicines are excluded," Pfizer CEO Albert Bourla said. -
Moderna Begins Trial On Omicron-Specific Booster Shot
Moderna said it will be conducting mid-stage studies on its new Omicron-specific booster in the U.S. 
Moderna said it will be conducting mid-stage studies on its new Omicron-specific booster in the U.S.
